Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,544,509
  • Shares Outstanding, K 94,036
  • Annual Sales, $ 31,430 K
  • Annual Income, $ -173,390 K
  • 60-Month Beta 1.67
  • Price/Sales 251.92
  • Price/Cash Flow N/A
  • Price/Book 10.01
Trade FATE with:

Options Overview

Details
  • Implied Volatility 72.24%
  • Historical Volatility 63.40%
  • IV Percentile 18%
  • IV Rank 19.77%
  • IV High 125.26% on 11/13/20
  • IV Low 59.17% on 06/14/21
  • Put/Call Vol Ratio 0.29
  • Today's Volume 273
  • Volume Avg (30-Day) 296
  • Put/Call OI Ratio 1.23
  • Today's Open Interest 6,794
  • Open Int (30-Day) 6,754

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.52
  • Number of Estimates 9
  • High Estimate -0.41
  • Low Estimate -0.59
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -48.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
65.13 +23.18%
on 06/03/21
90.99 -11.83%
on 06/14/21
+2.20 (+2.82%)
since 05/18/21
3-Month
65.13 +23.18%
on 06/03/21
95.33 -15.84%
on 03/22/21
-5.74 (-6.68%)
since 03/18/21
52-Week
29.37 +173.17%
on 09/04/20
121.16 -33.78%
on 01/14/21
+47.03 (+141.66%)
since 06/18/20

Most Recent Stories

More News
Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic, DVM,...

FATE : 80.23 (-4.73%)
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

Sector ETF report for SBIO

SBIO : 49.25 (+0.22%)
EBS : 60.55 (-4.07%)
FATE : 80.23 (-4.73%)
XLV : 123.74 (-1.14%)
VHT : 242.13 (-1.08%)
VIR : 46.15 (+5.32%)
Why Is Fate Therapeutics (FATE) Down 12.2% Since Last Earnings Report?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FATE : 80.23 (-4.73%)
Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting

8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response

FATE : 80.23 (-4.73%)
Fate Therapeutics to Present at Upcoming Investor Conferences

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will...

FATE : 80.23 (-4.73%)
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

Sector ETF report for SBIO

SBIO : 49.25 (+0.22%)
EBS : 60.55 (-4.07%)
FATE : 80.23 (-4.73%)
XLV : 123.74 (-1.14%)
VHT : 242.13 (-1.08%)
VIR : 46.15 (+5.32%)
Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia

4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow

FATE : 80.23 (-4.73%)
FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues

FATE reports a wider Q1 loss on increased R&D expenses.

JNJ : 161.98 (-1.96%)
GILD : 66.61 (-0.91%)
BMY : 66.47 (-0.45%)
FATE : 80.23 (-4.73%)
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -14.29% and 57.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

FATE : 80.23 (-4.73%)
Fate Therapeutics: Q1 Earnings Snapshot

SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Wednesday reported a loss of $45.1 million in its first quarter.

FATE : 80.23 (-4.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 89.22
2nd Resistance Point 87.02
1st Resistance Point 83.62
Last Price 80.23
1st Support Level 78.02
2nd Support Level 75.82
3rd Support Level 72.42

See More

52-Week High 121.16
Fibonacci 61.8% 86.10
Last Price 80.23
Fibonacci 50% 75.26
Fibonacci 38.2% 64.43
52-Week Low 29.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar